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 ABSTRACT 
 
 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not the 
addition of arginine protein supplementation is effective in wound healing of adult patients with 
stage II, III and IV pressure ulcers. 
 
STUDY DESIGN: Systematic review of three English language primary studies. One 
observation controlled study and two randomized controlled studies all published between 2010-
2012. 
 
DATA SOURCES: Two double blind randomized controlled trials and one observational 
controlled trial comparing the efficacy of arginine supplementation in wound healing of adult 
patients with stage II, III and IV pressure ulcers. All research articles were found using Cochrane 
Library EMB, Dynamed and Pubmed databases.  
 
OUTCOMES MEASURED: Pressure ulcer healing size and time were documented and 
compared using The National Pressure Ulcer Advisory Panel (PUSH) tool. The PUSH tool 
measures length x width, exudate amount and tissue type. Patients’ nutritional status and intake 
are also monitored throughout the studying using Subjective Global Assessment (SGA) tool.  
 
RESULTS: Two studies demonstrated significant decline in the ulcer size and healing time with 
the addition of arginine supplement. Brewer el al. showed patients receiving 9g of arginine daily 
has a mean healing time of 10.5 ±1.3 weeks compared to the historical group without arginine, 
which has mean healing time of 21.1±3.7 weeks. Van Anholt et al. demonstrated the intervention 
group receiving 9g of arginine has a significant decreased PUSH score, and  faster healing time 
(p≤0.012). The p-value calculated for the intervention group is p=0.006 and for the control group 
is p=0.016. Leigh et al. showed similar wound healing size and time for the 4.5g arginine control 
group and the 9g arginine intervention group. The PUSH score for the 4.5g arginine group is 
8.9±0.7, and for the 9g arginine group is 8.1±1.0. There is no significant difference in healing 
rate overall between the two groups, p=0.991. However, the time-to-heal rate decreased by half 
when compared both groups to historical data group receiving no supplement decreases the 
healing time.  
  
CONCLUSIONS: All three studies showed that arginine oral supplementation is effective in 
decrease pressure ulcer healing time and size in adult patients with stage II, III and IV pressure 
ulcers. And one study showed no significant differences between the different dosing of the 
supplement.   
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INTRODUCTION 
A pressure ulcer is the breakdown of skin, due to localized injuries, such as pressing or 
rubbing over areas of bony prominence. Common sites are heels, hips, elbows, knees, sacrum, 
coccyx and ankles.1,2  Pressure ulcers commonly affect those with medical conditions requiring 
prolonged immobility, thus hindering their ability to change positions. Once a pressure ulcer 
develops, it can progress rapidly and prove detrimental to patients. Arginine is an essential amino 
acid that plays an important role in protein synthesis, collagen deposition, and pressure ulcer 
healing.1 This systematic review paper evaluates two randomized controlled trials (RCTs) and 
one observational controlled trial, while comparing the efficacy of arginine oral supplements for 
wound healing of pressure ulcers stage II, III and IV in adults.  
The use of arginine supplements in treatment plans of patients with pressure ulcers is 
relevant to patients and physician assistant practice because pressure ulcers can cause serious 
complications such as cellulitis, sepsis, bone and joint infection. Furthermore, understanding the 
process of pressure ulcers and healing rate, will increase the likelihood physician assistants can 
treat patients, thus preventing ulcers.  The incidence of pressure ulcers is high in geriatric and 
bed bound patients. In 1993, 280,000 pressure ulcers were diagnosed in hospital stays, which 
almost doubled by 2004.3 The Centers for Disease Control and Prevention (CDC) estimates 11% 
of long-term residents in nursing homes suffered from various stages of pressure ulcers.4   
Subsequently, the cost of management and prolonged  length of stay are problems for the 
patients and healthcare facilities. Studies have shown that ~15% of geriatric patients develop 
new pressure ulcers within the first week of hospitalization, with an average charge of $43,180 
per stay for pressure ulcer treatment.3 Pressure ulcers are responsible for frequent emergency 
room visits and hospital admits. However, generally by the time a patients seeks help, their 
 condition has exacerbated to more than just topical cream treatment. It has been reported that 
pressure ulcers account for 2.7% to 9% of acute care settings and 2.4% to 23% in long-term care 
facilities.3,5  
The role of protein supplement in pressure ulcer healing is not well studied; however, it is 
believed that with adequate protein supplements, further breakdown of the soft tissues and 
muscles can be prevented.7 As the incidence rate and cost statistics shown above, healthcare 
providers can improve the health status of patients and reduce hospital costs with early 
intervention using proper and adequate nutritional supplementation.8  
Current treatments of pressure ulcers include daily cleansing and positioning of the 
wound by trained staff.  Normal saline is preferred by most facilities, with around the clock 
repositioning by wound care nursing technicians.4,5 Dressing and debridement of severe pressure 
ulcers using wet-to-dry dressing changing every 4 to 6 hours, and whirlpool devices for wounds 
with thick exudates. For patients with infected wounds, infection management is achieved by 
using topical antibiotics such as neomycin and bacitracin.5 Systemic antibiotics should be 
avoided since most of these patients are on multiple medications and are immunocompromised. 
Lidocaine-prilocaine cream and NSAIDs are mainstays for pain management. Adjunct therapy, 
such as nutrition management by adding protein supplements to meet 1.2 to 1.5g/kg/day, is 
widely used to improve patients’ protein status and improve wound healing.6 Arginine has shown 
to improve protein malnutrition in pressure ulcer patients, however, there are no structured 
guidelines and studies for the amount of proteins needed and its effectiveness. 
OBJECTIVES 
  The objective of this selective EBM review is to determine whether or not the addition of 
arginine protein supplementation is effective in wound healing of adult patients with stage II, III 
and IV pressure ulcers. 
METHODS 
 A number of criteria was thoroughly considered in the selection of studies. Studies were 
selected based on population, pressure ulcer stages and the type of intervention. The population 
was limited to patients > 18 years of age with no signs of malnutrition and diagnosed with at 
least one stage II to IV pressure ulcer. The intervention was 9g of oral arginine supplements 
daily.  
The randomized controlled studies compared the intervention group to the comparison group that 
received 9g of arginine supplement daily. The observational controlled group compared the 
intervention group to the comparison group of 17 historical control patients assessed by a 
medical history audit. The outcomes were measured to assess the improvement of the overall 
pressure ulcer and pressure ulcer healing size. Pressure ulcer healing size and time were 
documented and compared using The National Pressure Ulcer Advisory Panel (PUSH) tool.  All 
three studies were controlled trials, while two of the three studies are double blind randomized 
controlled trials and  one of the three is an observational controlled trial. 
A detailed search using Pubmed, Dynamed and Conchrane Library Database was performed 
using arginine, pressure ulcers, and wound healing as keywords. All three articles used in this 
review were written in English language and published in peer-reviewed journals between 2010 
and 2012. The author of this review conducted the research and the chosen articles were 
analyzed and selected based on topic relevance and patient oriented outcomes (POEMs). The 
inclusion criteria were studies that were randomized controlled trials published after 1996 using 
 arginine protein supplement as the sole intervention. The exclusion criteria were patients < 18 
years of age, body mass index <18.5kg/m2, on oral steroids, and/or receiving palliative care. The 
statistics reported and used by all three articles include ANOVA and p-value. Demographics of 
the three final selection are displayed in Table 1. 
Table 1: Demographics and characteristics of the selected studies 
 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Brewer1, 
2010 
Observational, 
controlled 
trials 
18 50± 
10 
years 
Bedbound 
spinal cord 
injury 
patients with 
stage 2,3 or 
4 pressure 
ulcers 
Patients with 
PKA, sepsis, 
chronic renal 
failure or 
metabolic 
disease 
1 9g of 
commercial 
powdered 
arginine 
supplement 
daily until 
full healing 
of the 
documented 
pressure 
ulcers 
Van 
Anholt4, 
2010  
RCT, double 
blind 
43 73± 5 
years 
At least one 
pressure 
ulcer stage 
III to IV 
receiving 
stand care 
and standard 
diet without 
prior 
nutritional 
supplements.  
BMI< 18.5 for 
patients 18-70 
years old, 
BMI< 21 for 
patients older 
than 70 years 
old. DM ulcers, 
life expectancy 
less than 6 mo, 
palliative care, 
use of steroids 
and anyone 
with dietary 
restrictions.  
11 Intervention 
group 
receives 
regular 
hospital diet 
with 9g of 
Arginaid 
each day. 
Comparison 
group 
receives 
regular 
hospital diet 
with 4.5g of 
Arginaid 
each day.  
Leigh2, 
2012  
RCT, double 
blind 
23 67± 5 
years 
Pressure 
ulcers stage 
2, 3, or 4 not 
showing 
Sepsis, acute 
gastrointestinal 
surgery, 
dialysis or 
7 One group 
receive 4.5 
of arginine 
and the other 
 signs of 
healing, on 
oral diet and 
has not 
received any 
oral 
supplement. 
individuals 
receiving 
hydroxyurea or 
prednisolone or 
dexamethasone.  
group 
receive 9g of 
arginine 
daily. 
 
OUTCOMES MEASURED 
The outcomes measured were patient oriented evidence that matters (POEMs), which 
includes pressure ulcer healing time and size. The initial pressure ulcer size and depth were 
measured at the time of enrollment and again at the end of the study. Pressure Ulcer Advisory 
Panel (PUSH) tool measures the length x width, exudate amount and wound tissue type. The 
PUSH score is used to assess the effectiveness of arginine supplement by measuring the 
outcomes of pressure ulcer healing size and time. A PUSH total score of 0 indicates completely 
healed and score of 17 indicated greatest severity.2 Patients’ nutritional status and oral intake 
were also monitored throughout the study using Subjective Global Assessment (SGA). SGA 
determines nutritional status of well nourished, moderately malnourished and severely 
malnourished by assessing patients’ recent weight change, dietary intake, signs of muscle 
wasting and gastrointestinal functional impairs.1 Van Anholt et al. also assessed the time spent 
changing the dressing between the intervention and control groups.  
RESULTS: 
Two double blind randomized controlled and one observational controlled trial were 
analyzed in this review. All participants in the studies are adults > 18 years of age, hospitalized 
and receiving care for documented stages II, III or IV pressure ulcers. Participants were followed 
by the same nursing staff if they were discharged from the hospital. All three studies excluded 
patients with sepsis, gastrointestinal surgery, on palliative care, history of metabolic disease such 
 as PKA, body mass index <18.5, and on dialysis. These exclusion criteria were selected due to 
the interference of arginine absorption and possible metabolic adverse reactions of taking protein 
supplements.1,2,9 Patients taking Hydroxyurea or prednisolone were also excluded because these 
drugs can affect the healing rate of pressure ulcers and wounds.1,2,9  
In Brewer et al., 26 pressure ulcers documented and healed in the historical control group 
were used to compare to the 30 pressure ulcers documented and healed in the intervention group. 
The results indicated the intervention group receiving 9g of arginine daily had significant faster 
time-to-healing rate than the historical control group receiving 4.5g of arginine daily. The 
findings proved the time-to-healing weeks were shortened by 50% in the intervention group.  
Also, the pressure ulcer area (cm2) is significantly reduced in the intervention group 4.5±1.3 
compared to the historical control group 6.7±0.3.1 The author pointed out that no documentation 
of baseline stages of pressure ulcers in the historical control group were available, therefore, no 
comparison can be done between each specific staging category.1  
Table 2: Time-to-healing of pressure ulcers reported by Brewers, et al. 
 
 Historical control 
time-to-healing weeks 
Intervention group 
time-to-healing weeks 
P value 
All pressure ulcer 
documented 
21.1 ± 3.7 (n=26) 10.5± 1.3 (n=30) 0.006 
Stage 2 N/A 5.5±1.3 (n=30) - 
Stage 3 N/A 12.5 ±1.9 (n=14) - 
Stage 4 N/A 14.4 ±2.6 (n=6) - 
Paraplegic 19.4 ±4.2 (n=13) 14.7 ± 4.6 (n=26) 0.586 
Quadriplegic  22.8 ± 6.2 (n=13) 10.4 ± 2.5 (n=4) 0.311 
 
The nursing staff visits the participants and monitors supplement compliance. Each arginine 
packet consumed was counted and checked against the amount of arginine the participant is 
 advised to take. The record showed compliance with the arginine supplement is at least 85% 
until full healing of the pressure ulcer. 13/18 participants consumed 100% of the arginine 
supplements provided throughout the study. No tolerance or adverse effects were discussed in 
this research article.1  
In Leigh, et al., the study showed no difference in time-to-healing rate between the 
control group receiving 4.5g of arginine and intervention group receiving 9g of arginine. Both 
groups took approximately 8 to 9 weeks to reach full healing with a p-value of 0.991.2  However, 
there was substantial decrease in PUSH scores over time, p<0.001.2 Table 3 shows the PUSH 
scores and healing rate for the two groups over the study period, calculated using repeated 
measure ANOVA. Because it is unjust and unethical to conduct a  placebo control group in a 
hospital in-patient setting, the author compared this study to a historical control group.2 The 
historical group participants had similar pressure ulcers and consumed similar amounts of energy 
and protein each day without the use of arginine oral supplements. The comparison showed that 
the full healing rate was 15.6 weeks for the historical group, which indicates a “two-fold 
improvement in both groups”2 receiving oral arginine supplements, regardless of the dosage. 
Table 3: Healing rate of pressure ulcers and PUSH tool reported by Leigh, et al.  
 Control group  
(4.5g Arginine) 
Intervention group 
(9g of Arginine) 
PUSH Score at Baseline 9 8 
PUSH Score in 3 weeks 5 5.5 
Healing Rate 8.7±0.7 weeks 8.4±1.0 weeks 
 
Compliance of the oral supplement was monitored by the nursing staff daily and recorded in the 
patients’ calorie count chart. The record showed the compliance with the oral supplement was 
90.3% for the control group and 93.3% for the intervention group.2 The author reported one 
 participant dropped out of the intervention group due to gastrointestinal side effects from 
arginine, but did not describe the presentation or the severity of the side effect.  
 In Van Anholt et al., the 8 weeks study showed significant decrease in pressure ulcer size 
in the intervention group, p=0.006. The healing of pressure ulcers was evidence in week 3 of the 
intervention group (p=0.019) and onward (p≤0.012).9 In the control group, the healing of the 
pressure ulcers were smaller compared to baseline in week 5 of the study (p=0.019) and onward 
(p≤0.008). Furthermore, the PUSH score of the intervention group improved significantly 
compared to the control group, p=0.011. Specifically, the intervention group had less 
documented necrotic or granulated ulcers and more closed ulcers than the control group, 
(p=0.037). Lastly, the time spent on dressing change on each pressure ulcer showed that less time 
is spent on dressing change in the intervention group, p=0.006.9  
Table 4:  Average numbers of dressing required per wound per week reported Van Anholt et al.  
 Intervention Group Control Group 
Baseline dressings 5.5 4.8 
# of dressings weekly in week 1 5.8 5.5 
# of dressings weekly in week 2 5.5 5.5 
# of dressings weekly in week 3 5 5.6 
# of dressings weekly in week 4 5 5.5 
# of dressings weekly in week 5 4.5 5.5 
# of dressings weekly in week 6 4.3 5.6 
# of dressings weekly in week 7 4 5.5 
# of dressings weekly in week 8 4.3 5.2 
 
The compliance of the supplement was documented each time participants consumed a study 
supplement along with a questionnaire regarding gastrointestinal tolerance and adverse effects. 
 The record showed that the compliance rate is 75.8±3.7% and 86.5±2.3% for the intervention 
and control group respectively.9 The author reported a total of 13 adverse effects were reported to 
be related to the study product.9 Most of the complaints were gastrointestinal intolerance such as 
diarrhea, dyspepsia and constipation. Diarrhea is found to be more severe in the intervention 
group, averaging six times a day. Total of two participants from the intervention group dropped 
out due to tolerability and the taste of the oral supplement.9 
Table 5: Adverse Events Across Trials (# of participants monitored) 1,2,9 
 Brewer el al. (18) Leigh et al. (23) Van Anholt et al. (43) 
Total GI AEs n/a 1 13 
Diarrhea n/a n/a 8 
Constipation n/a n/a 1 
Dyspepsia n/a n/a 1 
N/V n/a n/a 3 
 
DISCUSSION: 
 The use of arginine as a daily oral protein supplement daily has proven effective in 
pressure ulcer healing rate and size. Although the exact dosage needed is unknown, most 
hospitals and nursing homes implement protein supplement usage with the assist of clinical 
dietitians. Arginine comes in both powder and liquid forms and is readily available in 
pharmacies, health stores such as GNC and supermarkets with no prescription required. Online 
price search shows the prices of arginine supplements ranged from $7 to $40 depending on the 
 size and strength of the supplement. For patients with Medicare part B, billing code B4155 can 
be used for billing, but does not guarantee claim reimbursement.12 The coverage for Medicaid 
varies by state. Most hemodialysis and severe malnourished patients with documented albumin 
or pre-albumin status are eligible for coverage. 
  An unexpected finding was revealed in Leigh et al. The study has an even 
distribution of participants who were categorized as well-nourished and malnourished using the 
SGA tool. The author was able to assess the effect of baseline nutritional status at the beginning 
of the study and pressure ulcer healing rate. The study revealed that participants who are well-
nourished from the start had less severe pressure ulcers at the end of the study regardless of the 
treatment group.2 
Throughout the three studies, there were limitations that may have affected the results of 
each study. In Brewer et al, the small sample size of 18 participants could have hindered the 
chance of detecting the true benefits of arginine and reduce the statistical control. Furthermore, 
the use of historical data instead of double blind research method does not reveal important 
information such as nutritional status and the initial PUSH scores of the historical patient cohort. 
Therefore, comparisons within each pressure ulcer stages were impossible. One of the major 
limitations in Leigh et al was that the pressure ulcer healing rate was assessed over a 3-week 
period instead of time-to-heal method. The effect of arginine after 3 weeks cannot be determined, 
and thus the long-term effectiveness of arginine cannot be determined. However, the author 
pointed out that one previous research showed “clinically significant evidence in pressure ulcer 
healing in 3 weeks”, therefore, a 3-week time frame is practical and provides valid results.2 Van 
Anholt et al. and Brewer et al. both discussed the inability to control the nursing schedules and 
 methods of dressing changes. Although wound care education was provided to the nursing staff, 
each patient is different and dressing change methods was individualized.1,9 
 Arginine is considered relatively safe oral supplement with minimal adverse reactions. 
Some studies have shown that 1% to 10% of participants given >10 g of arginine single doses 
can cause constipation, vomiting or diarrhea in ill patients.10 Although rare, other uses of 
arginine include congestive heart failure, chest pain and wasting in HIV/AIDS patients.11  
Intravenous arginine has been used in pediatric patients for the treatment of pituitary dwarfism. 
The FDA reported recent incidence of pediatric overdosing of arginine hydrochloride injection 
due to packaging and mislabeled confusion.11 The product’s packaging and labeling has been 
modified since.  There are no known contraindications for arginine oral supplement, but keep in 
mind to use with caution in patients with impaired kidney function, and taking potassium 
supplements as arginine may cause high potassium level in the blood. As of 2013, only one fatal 
cardiac arrhythmia incidence has been reported.11  
CONCLUSION: 
All three studies analyzed have shown that arginine oral supplement is effective in 
pressure ulcer healing time and size in adult patients with stage II, III and IV pressure ulcers. 
Accelerated wound healing not only improves the quality of life, but also plays an important role 
in reducing the cost of healthcare and the length of stay. Which in turn, complications such as 
sepsis, amputation and death can be prevented. Although it is vital to treat pressure ulcers, 
prevention should be included as the treatment plan as well. Future studies should use larger 
sample size and focus on the dosage needed for prevention. 
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